Comparing the Efficacy and Safety of Venetoclax Combined With Decitabine Versus Conventional "7+3" Induction Chemotherapy of Acute Myeloid Leukemia in Young Adults

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Decitabine (Primary) ; Gilteritinib (Primary) ; Venetoclax (Primary) ; Cytarabine; Idarubicin
Indications Acute myeloid leukaemia
Focus Therapeutic Use

05 Jun 2024 Status changed from recruiting to active, no longer recruiting.
12 Dec 2023 Interim results (Since March 2022; n=116) assessing efficacy and safety of venetoclax combined with decitabine versus intensive chemotherapy (idarubicin and cytarabine) in newly diagnosed acute myeloid leukemia patients, presented at the 65th American Society of Hematology Annual Meeting and Exposition
28 Feb 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com